ClinicalTrials.gg

Program

TQH3906

A development code. Also written as “TQH3906 capsules”, “TQH3906 capsule” and “TQH3906 Capsule”.

In Sino Biopharmaceutical's pipeline, TYK2抑制剂. Its studies are mostly in Psoriasis · Arthritis, Psoriatic · Lupus Erythematosus, Systemic · Inflammatory Bowel Diseases, led by Sino Biopharmaceutical.

Furthest: phase 3, since Jul 21, 20266 company-led studies, 4 open or runningNext primary completion: Jul 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sino Biopharmaceutical64 open or runningphase 3since Jul 21, 2026Jan 21, 2024Jul 2027phase 1 · NCT06754891
  • Named in Sino Biopharmaceutical’s own pipeline as TQH3906, phase 2, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 21, 2024First study: phase 1 study in PsoriasisFirst studyNCT06230588 · 96 enrolled · China
  2. Aug 5, 2024Phase 2 study in Plaque PsoriasisNCT06542614 · 209 enrolled · China
  3. Dec 25, 2024Phase 1 study in Inflammatory Bowel DiseasesNCT06754891 · 135 planned · China
  4. Jan 29, 2026Phase 2 study in Arthritis, PsoriaticNCT07406035 · 156 planned · China
  5. Mar 28, 2026Phase 2 study in Lupus Erythematosus, SystemicNCT07509892 · 198 planned · China
  6. Jul 21, 2026Phase 3 study in PsoriasisPhase 3 reachedNCT07724366 · 400 planned · China

Ahead

  1. Jul 2027Primary completion: phase 1 study in Inflammatory Bowel DiseasesNCT06754891
  2. Aug 2027Primary completion: phase 2 study in Arthritis, PsoriaticNCT07406035
  3. Sep 2027Primary completion: phase 3 study in PsoriasisNCT07724366
  4. Nov 2027Primary completion: phase 2 study in Lupus Erythematosus, SystemicNCT07509892

TargetBeta

“TYK2抑制剂”the company's pipeline, read by Claude · source

Other programs on TYK2

ProgramCompanyFurthest phaseStudies
ruxolitinibruleIncytephase 495
tofacitinibrulePfizerphase 494
upadacitinibruleAbbViephase 464
deucravacitinibruleBristol-Myers Squibbphase 460
filgotinib maleateruleEisaiphase 42
filgotinibruleLakefront Biotherapeutics NVphase 346
brepocitinibrulePfizerphase 325
delgocitinibruleLEO Pharmaphase 321
D-2570ruleInventisBiophase 313
HS-10374Hansoh Pharmaceutical Groupphase 36
FXS5626Fosun Pharmaphase 33
TYK2 Inhibitorruleusynova-pharmaceuticals-ltdno phase1

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07724366Psoriasis · China3RecruitingSep 2027400
NCT07509892Lupus Erythematosus, Systemic · China2RecruitingNov 2027198
NCT07406035Arthritis, Psoriatic · China2RecruitingAug 2027156
NCT06754891Inflammatory Bowel Diseases · China1RecruitingJul 2027135
NCT06542614Plaque Psoriasis · China2CompletedNov 3, 2025209
NCT06230588Psoriasis · China1CompletedApr 27, 202596

How it is read

Names in the registry

  • “TQH3906 capsules”, 2 entries
  • “TQH3906 capsule”, 2 entries
  • “TQH3906 Capsule”, 1 entry
  • “24mg bid TQH3906 capsule”, 1 entry
  • “32mg TQH3906 capsule”, 1 entry

Codes read as this program: TQH3906.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.